Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
Open Access
- 30 June 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (12) , 1985-1992
Abstract
Background: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT. Materials and methods: Four hundred and seventy-six patients Results: At a median of 4 years’ follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. Conclusion: The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months’ follow-up.Keywords
Funding Information
- Programme Hospitalier de Recherche Clinique (PHRC-AOM 98-117)
This publication has 31 references indexed in Scilit:
- Dose‐escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem‐cell transplantation in poor‐risk aggressive B‐cell lymphoma: a prospective study from the GEL–TAMO Study GroupEuropean Journal of Haematology, 2007
- High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysisCancer Treatment Reviews, 2007
- Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphomaBlood, 2006
- Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphomaBlood, 2006
- Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell SupportNew England Journal of Medicine, 2004
- Impact of High-Dose Chemotherapy on Peripheral T-Cell LymphomasJournal of Clinical Oncology, 2002
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte StudyJournal of Clinical Oncology, 2000
- High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell LymphomaNew England Journal of Medicine, 1997
- Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.Journal of Clinical Oncology, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993